Curasight

Presentationerna kommer att omfatta en genomgång av nyemissionen av aktier och en uppdatering om företagets framsteg under första kvartalet 2025. Dessutom kommer ledningen att informera investerare om de senaste utvecklingarna under första kvartalet och förväntade nyheter om pipeline. HC Andersen Capitals presentation kommer att sändas live mellan 13:00 och 13:30 (CET) fredagen den 2 maj 2024 med fokus på den pågående nyemissionen. En arkiverad version av presentationen kommer att finnas tillgänglig på HC Andersen Capitals och Curasights webbplatser efter att presentationen är avslutad. För mer information om Curasight kan man kontakta Ulrich Krasilnikoff, VD, via telefon eller e-post.

Curasight has prepared a disclosure document for a Rights Issue in compliance with the EU Prospectus Regulation. This document is registered with the Danish Financial Supervisory Authority and is available on Curasight's website. Shareholders can subscribe to new shares through their financial institutions using a subscription form provided on the website. Key dates include the trading of subscription rights from April 30 to May 14, 2025, and the subscription period from May 2 to May 16, 2025. The outcome will be published on May 21, 2025. Each existing share will entitle the holder to 43 subscription rights, and 18 rights are needed to subscribe for one new share. Sedermera Corporate Finance AB is coordinating the issue, with DLA Piper as legal advisor and Danske Bank as the settlement agent. Contact details for further information are provided for both Sedermera Corporate Finance and Curasight's CEO, Ulrich Krasilnikoff.

Under 2024 upplevde Curasight ett hektiskt år med framsteg inom klinisk utveckling trots en utmanande makroekonomisk miljö. Företaget intensifierade sina affärsutvecklingsaktiviteter och diskussioner med branschaktörer om potentiella strategiska partnerskap, vilket stärkte deras strategiska investerarbas. Curium och Pentwater kommer att bli aktieägare i samband med en kapitalanskaffning under första halvåret 2025. Curasight fortsatte att arbeta med sin strategi för att påskynda den kliniska utvecklingen av uTREAT®, med hjärncancer som första indikation för en klinisk prövning. Företaget siktar på att utveckla både diagnostiska och terapeutiska alternativ parallellt. Finansiellt redovisade Curasight en bruttovinstförlust på -32,731 kDKK, en rörelseförlust på -40,367 kDKK, och en förlust före skatt på -42,336 kDKK. Årets förlust uppgick till -36,836 kDKK, med totala tillgångar på 23,688 kDKK och en soliditet på 32,6%. Resultatet per aktie var -1,74 DKK. Bland årets affärshöjdpunkter ingick att Curasight uppnådde flera milstolpar i samarbetet med Curium Inc. för utvecklingen av uTRACE® PET-avbildningsteknik för prostatacancer. De fick godkännande från EMA för en klinisk prövning av uTRACE® som ett icke-invasivt alternativ till traditionella biopsier. De första patienterna inkluderades i en fas 2-studie, och företaget genomförde riktade emissioner av aktier och säkrade en lånefacilitet. En rättighetsemission blev kraftigt övertecknad. Curasight meddelade också hjärncancer som den första indikationen för uTREAT och offentliggjorde en internationell patentansökan för teknologin. De ingick även ett avtal med Curium för leverans av Lutetium-177 för uTREAT.

Curasight's CEO, Ulrich Krasilnikoff, reported that during the first quarter of 2025, the company focused on securing financial resources to advance its uTRACE® and uTREAT® platforms. Despite macroeconomic challenges, Curasight announced a rights issue to raise approximately DKK 100 million, with DKK 65 million already secured. This includes DKK 47 million from pre-subscriptions and guarantee commitments, notably from new strategic shareholders Curium and Pentwater. The company anticipates achieving key clinical milestones in 2025, including the completion of a phase II study in prostate cancer and a phase I study in aggressive brain cancer. Financial results for Q1 2025 show a gross loss of kDKK -4,699, an operating loss of kDKK -6,209, and a loss before tax of kDKK -6,579. The loss for the period was kDKK -5,204, with total assets at kDKK 17,660 and an equity ratio of 14.2%. Earnings per share were DKK -0.25. These figures are compared to the same period in 2023, which showed larger losses and a higher equity ratio. For more details, contact Ulrich Krasilnikoff.

Curasight plans a Rights Issue to raise approximately DKK 100 million, with a subscription price set at DKK 1.98 per share. Existing shareholders will receive one subscription right per share, where 18 rights allow the purchase of 43 new shares. The issue is supported by commitments from partners like Curium and Pentwater, covering 27.7% of the offering, and external guarantees covering an additional 19.3%, totaling about 47% coverage. The record date is 1 May 2025, with the subscription period from 2 to 16 May 2025. The proceeds will fund ongoing clinical trials and operations until mid-2026. No prospectus will be issued; instead, an information document will be published. The offering is not registered in several jurisdictions, including the US, and is aimed at qualified investors in the EEA and UK.

At an Extraordinary General Meeting, Curasight's shareholders approved several proposals from the Board of Directors. These included extending and increasing the Board's authorization to raise the company's share capital both with and without pre-emption rights, allowing the issuance of up to DKK 100,000,000 in shares until March 21, 2029. Additionally, a new authorization was introduced for the Board to issue up to 106,375,256 warrants, enabling subscription for up to DKK 5,318,812 in shares without pre-emption rights until April 16, 2030. The Board can also reuse or reissue any lapsed warrants. Lastly, the chairman of the meeting, Ulrik Bangsbo Hansen, was authorized to register the resolutions and make necessary amendments. For further details, contact CEO Ulrich Krasilnikoff.

The Board of Directors has proposed several agenda items for an upcoming Extraordinary General Meeting. These include extending and increasing authorizations for the Board to raise the company's share capital, both with and without pre-emption rights, by a total nominal amount of DKK 100,000,000. Additionally, they propose authorizing the issuance of up to 106,376,256 warrants to obtain financing, valid until April 16, 2030. The Board also seeks authorization for the meeting chairman to register resolutions and make necessary adjustments as required by authorities. Voting on these proposals requires varying majorities, with specific requirements outlined in the Danish Companies Act. Shareholders are invited to participate, vote, and ask questions, with various options for proxy and postal voting provided. The meeting will be conducted in Danish, and further information is available on the company's website.

Curasight plans to raise approximately DKK 100 million through a Rights Issue, with final terms expected to be announced on April 24, 2025. The subscription price will be set at 65% of the theoretical ex-rights price, but not lower than the nominal share value, capped at DKK 10.24. The Rights Issue is partially covered by subscription and guarantee commitments totaling about 47% of the issue. The record date is tentatively set for May 1, 2025, with a subscription period from May 2 to May 16, 2025. Curasight has renegotiated an outstanding loan with Fenja Capital and secured a bridge loan of DKK 8 million, with warrants issued to Fenja Capital. The funds raised will support ongoing clinical trials and operational costs until mid-2026. The Rights Issue is subject to approval at an Extraordinary General Meeting on April 23, 2025. Sedermera Corporate Finance AB is coordinating the issue, and further details will be published in an information document on April 29, 2025.

Curasight har planerat sin årsstämma till den 28 maj 2025, vilket har uppdaterat den finansiella kalendern och informationen i årsrapporten för 2024. Följande datum är schemalagda för 2025: sista dag för inlämning av aktieägarförslag till årsstämman är den 5 maj, årsrapporten för 2024 publiceras den 13 maj, årsstämman hålls den 28 maj, delårsrapport för Q1 2025 presenteras den 28 maj, delårsrapport för första halvåret 2025 den 28 augusti, och delårsrapport för Q3 2025 den 27 november. För ytterligare information kan Ulrich Krasilnikoff, VD, kontaktas via telefon eller e-post.

Curasight's CEO, Ulrich Krasilnikoff, reported on the company's progress in the fourth quarter, highlighting advancements in their therapeutic and diagnostic platforms, uTREAT® and uTRACE®. They chose brain cancer as the initial clinical focus for uTREAT, aiming for a quicker proof of concept. The company also pursued business development and potential industry collaborations while exploring strategic fundraising despite macroeconomic challenges. Financially, the fourth quarter showed increased losses compared to the same period in 2023, with a gross loss of kDKK -10,210, operating loss of kDKK -11,721, and a loss before tax of kDKK -12,334. Total assets decreased to kDKK 22,314, and the equity ratio dropped to 28.4%. For the full year, the gross loss was kDKK -32,731, operating loss kDKK -40,367, and loss before tax kDKK -42,336. Curasight plans to release its 2024 Annual Report on March 26, 2025.